Shoji Tadahiro, Takatori Eriko, Kaido Yoshitaka, Kumagai Seisuke, Takeuchi Satoshi, Yoshizaki Akira, Sugiyama Toru
Department of Obstetrics and Gynecology, Iwate Medical University School of Medicine, Iwate 020-8505, Japan.
Oncol Lett. 2010 Nov;1(6):1021-1023. doi: 10.3892/ol.2010.192. Epub 2010 Sep 23.
We report a case of recurrent ovarian cancer in which desensitization for a carboplatin hypersensitivity reaction proved useful. The patient was a 65-year-old woman who presented with a recurrence of stage IIIc ovarian cancer. The initial chemotherapy consisted of 6 courses of paclitaxel and carboplatin. Recurrence in the pelvis, splenic hilum and para-aortic lymph nodes was detected 19 months after the final day of treatment. The patient was treated with docetaxel-carboplatin therapy for the recurrence, but a Grade 3 hypersensitivity reaction to carboplatin was observed during the second course. Carboplatin desensitization was commenced with the third course and 6 courses were completed with no evidence of hypersensitivity reaction. The antitumor effect showed a complete response and the patient has had a disease-free survival thus far. Desensitization for patients diagnosed with a carboplatin hypersensitivity reaction appeared to be a key method of treatment for prolonging the survival time of patients with recurrent ovarian cancer.
我们报告了一例复发性卵巢癌病例,其中对卡铂过敏反应进行脱敏治疗被证明是有效的。患者为一名65岁女性,表现为Ⅲc期卵巢癌复发。初始化疗包括6个疗程的紫杉醇和卡铂。在治疗最后一天后的19个月,检测到盆腔、脾门和主动脉旁淋巴结复发。患者复发后接受多西他赛-卡铂治疗,但在第二个疗程中观察到对卡铂的3级过敏反应。从第三个疗程开始进行卡铂脱敏治疗,共完成6个疗程,未出现过敏反应迹象。抗肿瘤效果显示完全缓解,患者迄今为止无病生存。对于诊断为卡铂过敏反应的患者,脱敏似乎是延长复发性卵巢癌患者生存时间的关键治疗方法。